sofidexFor patientsAre you a clinician? Clinical site

Meds & supplements  ›  Thalidomide

Medicine

Thalidomide

THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM).

Medication guideLabel updated 2023-03-24

Selected manufacturer label information, organised into consistent sections by Sofidex. Read the full label at DailyMed ↗

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY AND VENOUS THROMBOEMBOLISM See full prescribing information for complete boxed warning. EMBRYO -FETAL TOXICITY • If THALOMID is taken during pregnancy, it can cause severe birth defects or embryo-fetal death. THALOMID should never be used by females who are pregnant or who could be pregnant while taking the drug. Even a single dose [1 capsule (regardless of strength)] taken by a pregnant woman during her pregnancy can cause severe birth defects. • Pregnancy must be excluded before start of treatment. Prevent pregnancy thereafter by the use of two reliable methods of contraception. THALOMID is only available through a restricted distribution program, the THALOMID REMS ® program. VENOUS THROMBOEMBOLISM • Significant increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with multiple myeloma receiving THALOMID with dexamethasone. THALOMID should never be used by females who are pregnant or who could become pregnant while taking the drug. Because of this toxicity and in an effort to make the chance of embryo-fetal exposure to THALOMID as negligible as possible, THALOMID is approved for marketing only through a special restricted distribution program: THALOMID REMS program, approved by the Food and Drug Administration. Information about THALOMID and the THALOMID REMS program is available at www.thalomidrems.com or by calling the REMS Call Center at 1-888-423-5436. VENOUS THROMBOEMBOLISM The use of THALOMID in multiple myeloma results in an increased risk of venous thromboembolism, such as deep venous thrombosis and pulmonary embolism. This risk increases significantly when THALOMID is used in combination with standard chemotherapeutic agents including dexamethasone. In one controlled trial, the rate of venous thromboembolism was 22.5% in patients receiving THALOMID in combination with dexamethasone compared to 4.9% in patients receiving dexamethasone alone (p = 0.002). Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Instruct patients to seek medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Consider thromboprophylaxis based on an assessment of individual patients' underlying risk factors.

Drug facts

Used for
  • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
  • THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.
  • THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.
How to take it
Take THALOMID exactly as prescribed and follow all the instructions of the THALOMID REMS program.

What it is used for

THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis.

THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. Multiple Myeloma THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). Erythema Nodosum Leprosum THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

The most important thing to know

Before you begin taking THALOMID, you must read and agree to all of the instructions in the THALOMID REMS® program. For more information, call 1-888-423-5436 or go to www.thalomidrems.com. Before prescribing THALOMID, your healthcare provider will explain the THALOMID REMS program to you and have you sign the Patient-Physician Agreement Form.

THALOMID can cause serious side effects including: Severe and life-threatening human birth defects (deformed babies) or death of an unborn baby. Females who are pregnant or who plan to become pregnant must not take THALOMID. Females must not get pregnant: o For at least 4 weeks before starting THALOMID o While taking THALOMID o During any breaks (interruptions) in your treatment with THALOMID o For at least 4 weeks after stopping THALOMID Females who can become pregnant: o Will have pregnancy tests weekly for 4 weeks, then every 4 weeks if your menstrual cycle is regular, or every 2 weeks if your menstrual cycle is irregular.

o If you miss your period or have unusual bleeding, you will need to have a pregnancy test and receive counseling. o Must agree to use two acceptable forms of birth control at the same time, for at least 4 weeks before, while taking, during any breaks (interruptions) in your treatment, and for at least 4 weeks after stopping THALOMID.

o Talk with your healthcare provider to find out about options for acceptable forms of birth control that you may use to prevent pregnancy before, during, and after treatment with THALOMID. o Stop taking THALOMID and call your healthcare provider right away if you have unprotected sex or if you think your birth control has failed.

If you become pregnant while taking THALOMID, stop taking it right away and call your healthcare provider. If your healthcare provider is not available, you should call the REMS Call Center at 1-888-423-5436. Healthcare providers and patients should report all cases of pregnancy to: o FDA MedWatch at 1-800-FDA-1088, and o REMS Call Center at 1-888-423-5436 There is a pregnancy exposure registry that monitors the outcomes of females who take THALOMID during pregnancy, or if their male partner takes THALOMID and they are exposed during pregnancy.

You can enroll in this registry by calling the REMS Call Center at the phone number listed above. THALOMID can pass into human semen: o Males, including those who have had a vasectomy, must always use a latex or synthetic condom during any sexual contact with a pregnant female or a female that can become pregnant while taking THALOMID, during any breaks (interruptions) in your treatment with THALOMID, and for up to 4 weeks after stopping THALOMID.

o Do not have unprotected sexual contact with a female who is or could become pregnant. Tell your healthcare provider if you do have unprotected sexual contact with a female who is or could become pregnant. o Do not donate sperm while taking THALOMID, during any breaks (interruptions) in your treatment, and for 4 weeks after stopping THALOMID.

If a female becomes pregnant with your sperm, the baby may be exposed to THALOMID and may be born with birth defects. Men, if your female partner becomes pregnant, you should call your healthcare provider right away. Blood clots. People with multiple myeloma (MM) who take THALOMID may have an increased risk for blood clots in their arteries, veins, and lungs.

This risk is even higher if you take the medicine dexamethasone with THALOMID to treat your MM. Heart attacks and strokes may also happen if you take THALOMID with dexamethasone. Before taking THALOMID, tell your healthcare provider about all the medicines you take. Certain other medicines can also increase your risk for blood clots.

Call your healthcare provider or get medical help right away if you get any of the following during treatment with THALOMID: o Signs or symptoms of a blood clot in the lung, arm, or leg may include: shortness of breath, chest pain, or arm or leg swelling o Signs or symptoms of a heart atta

How to take it

Take THALOMID exactly as prescribed and follow all the instructions of the THALOMID REMS program. Keep THALOMID in the blister pack until you take your daily dose. Swallow THALOMID capsules whole with water. THALOMID is taken 1 time each day, at least 1 hour after your evening meal. Bedtime is the preferred time to take THALOMID.

Do not open or crush THALOMID capsules or handle them any more than needed. o If powder from the THALOMID capsule comes in contact with your skin, wash the skin right away with soap and water. o If powder from the THALOMID capsule comes in contact with the inside of your eyes, nose, and mouth, flush well with water. If you miss a dose of THALOMID and it has been less than 12 hours since your regular time, take it as soon as you remember.

If it has been more than 12 hours, just skip your missed dose. Do not take 2 doses at the same time. If you take too much THALOMID, call your healthcare provider right away.

Side effects, and when to stop

THALOMID can cause serious side effects, including: Drowsiness and sleepiness. See "What should I avoid while taking THALOMID?" Nerve damage. Nerve damage is common with THALOMID. If the nerve damage is severe, it may not go away. Stop taking THALOMID and call your healthcare provider right away if you have any of these early symptoms of nerve damage in your hands, legs, or feet: o numbness o tingling o pain o burning sensation Dizziness and decreased blood pressure when changing positions.

THALOMID may cause a decrease in your blood pressure, and you may feel dizzy when you go from a lying down or sitting position to standing up. When changing positions, sit upright for a few minutes before standing to help prevent this. Decreased white blood cell count. THALOMID can cause decreased white blood cell counts, including neutrophils.

Neutrophils are a type of white blood cell that is important in fighting bacterial infections. Your healthcare provider should check your white blood count before and regularly while you take THALOMID. If your neutrophils are too low you should not start THALOMID and if they are low during treatment, your dose of THALOMID may need to be changed.

Decreased platelet count. THALOMID can cause decreased platelet counts. Your healthcare provider should check your platelet count before and regularly while you take THALOMID. If your platelets are too low, your healthcare provider may lower your dose, delay your dose, or completely stop treatment. Tell your healthcare provider if you have signs and symptoms of bleeding such as: o small red or purple spots on your body o unusual bleeding or bruising o nosebleeds o bright red or tar like stools o vomiting or coughing up blood Increased HIV virus in the blood.

If you are HIV positive, your healthcare provider should check your viral load after one month and three months of treatment, then every 3 months after that. Slow heartbeat (bradycardia). Tell your healthcare provider if you have a slow heartbeat, fainting, dizziness or shortness of breath. Severe skin reactions and severe allergic reactions.

Severe skin reactions and severe allergic reactions can happen with THALOMID and may cause death. Call your healthcare provider right away if you develop any of the following signs or symptoms during treatment with THALOMID: o a red, itchy, skin rash o peeling of your skin or blisters o severe itching o fever Get emergency medical help right away if you develop any of the following signs or symptoms during treatment with THALOMID: o swelling of your lips, mouth, tongue, or throat o trouble breathing or swallowing o raised red areas on your skin (hives) o a very fast heartbeat o you feel dizzy or faint Seizures.

Tell your healthcare provider right away if you have a seizure while taking THALOMID. Tumor Lysis Syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure and sometimes death. Your healthcare provider may do blood tests to check you for TLS.

Birth control risks. Certain birth control methods may pose a higher risk of serious side effects and should not be used in some females. These risks include severe decreased white blood cell counts, low platelet counts, and blood clots. Use of an intrauterine device (IUD) or implantable birth control may also increase your risk of infection or bleeding during insertion, removal or during use of the device.

Your healthcare provider may tell you to decrease your dose, temporarily stop or permanently stop taking THALOMID if you develop certain serious side effects during treatment with THALOMID. The most common side effects of THALOMID for treatment of multiple myeloma include: tiredness decreased calcium levels swelling of the hands and feet constipation numbness or tingling shortness of breath muscle weak

Who should not take it

Do not take THALOMID if you: are pregnant, plan to become pregnant, or become pregnant during treatment with THALOMID. are allergic to thalidomide or any of the ingredients in THALOMID. See the end of this Medication Guide for a complete list of ingredients in THALOMID.

What to say before you start

Before you take THALOMID, tell your healthcare provider about all of your medical conditions, including if you: have a history of seizures drink alcohol plan to have surgery are breastfeeding. THALOMID must not be used by females who are breastfeeding. It is not known if THALOMID passes into your breast milk and can harm your baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. THALOMID and other medicines may affect each other, causing serious side effects. Talk with your healthcare provider before taking any new medicines. Certain medicines can affect the way that birth control pills, injections, transdermal systems (patches), or implants work.

You could become pregnant. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist.

What to avoid

Females: Do not get pregnant and do not breastfeed while taking THALOMID. Males: Do not donate sperm. Do not share THALOMID with other people. It may cause birth defects and other serious problems. Do not donate blood while you take THALOMID, during any breaks (interruptions) in your treatment, and for 4 weeks after stopping THALOMID.

If someone who is pregnant gets your donated blood, her baby may be exposed to THALOMID and may be born with birth defects. THALOMID can cause drowsiness and sleepiness. Avoid drinking alcohol, operating machinery, and driving a car when taking THALOMID. Avoid taking other medicines that may cause drowsiness without talking to your healthcare provider first.

Storing it

Store THALOMID at room temperature between 68°F to 77°F (20°C to 25°C). Protect from light. Return any unused THALOMID to THALOMID REMS by calling 1-888-423-5346 or your healthcare provider. Keep THALOMID and all medicines out of the reach of children.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Thalidomide; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/thalidomide

APA 7th

sofidex. (2026, August 2). Thalidomide. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/thalidomide

AMA 11th

Thalidomide. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/thalidomide

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.